November 7 (SeeNews) - Bulgarian pharmaceuticals producer Sopharma [BUL:SFA] said on Monday that its sales rose by 30% year-on-year in October on the back of strong exports.
The company recorded in October a 13% decline in domestic sales, but its exports jumped 58% on the year, it said in a stock exchange filing.
In the first ten months of 2022, Sopharma's sales increased by 19% in annual terms, including 12% growth in domestic sales and a 23% rise in exports.
The drug maker reported at the end of October a standalone net profit of 25.4 million levs ($12.95 million/12.99 million euro) for the first nine months of 2022, up from 22.4 million levs in the same period of 2021.
As at 1451 CET on Monday, shares in Sopharma traded flat at 4.48 levs on the Bulgarian Stock Exchange.
The company has a portfolio of over 200 products, mainly generic drugs.
(1 euro = 1.95583 levs)